醫脈通(02192.HK)挫16% 去年少賺52%末期股息1.7分人幣
上市不足一年的醫脈通(02192.HK)去年少賺52%,末期股息1.7分人民幣。該股今早重失10天及20天線(9.55元及9.85元),最低見9.05元,現報9.1元,急吐16%,成交增至89萬股,涉資862萬元。
內地最大的在線專業醫師平臺醫脈通公佈,去年純利按年倒退52%至4,062萬元人民幣(下同),每股盈利6.59分,末期股息1.7分。期內,總收入按年升33%至2.84億元。
醫脈通去年7月以每股27.2港元來港上市,掛牌後股價於去年11月曾升至47港元遇阻輾轉滑落,本月15日曾跌7.42港元上市新低喘定回升。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.